STOCK TITAN

Elite Pharmaceuticals, Inc. - ELTP STOCK NEWS

Welcome to our dedicated news page for Elite Pharmaceuticals (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elite Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elite Pharmaceuticals's position in the market.

Rhea-AI Summary
Elite Pharmaceuticals, Inc. reported strong financial results for the third quarter of fiscal year 2024, with consolidated revenues of $15.5 million, a 68% increase from the previous year. Operating profits also rose by 80% to $3.5 million, driven by increased sales of Elite Laboratories label products. A conference call is scheduled for February 15, 2024, to discuss the financial results and recent business developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
earnings
-
Rhea-AI Summary
Elite Pharmaceuticals, Inc. will release its financial results for the third quarter of fiscal year 2024 on February 14, 2024. The company will host a live conference call on February 15th to discuss the results and provide a general business update. Stockholders are encouraged to submit questions before the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences earnings
-
Rhea-AI Summary
Elite Pharmaceuticals, Inc. (ELTP) announced FDA acceptance for review of an Abbreviated New Drug Application (ANDA) for an undisclosed generic drug product in the central nervous stimulants class. IQVIA reported annual sales of $5.1 billion for the brand and generic market for this product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Elite Pharmaceuticals, Inc. (ELTP) has announced the first shipment of generic Adderall XR to its partner Prasco, LLC. The extended-release mixed salt of a single entity Amphetamine product will be distributed by Prasco under Burel Pharmaceutical's label, pursuant to the manufacturing and supply agreement between the companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Announces Strong Second Quarter Fiscal Year 2024 Results with 64.9% Revenue Increase and 886% Net Income Growth. Conference Call Scheduled for November 15 at 11:30 AM EST to Discuss Financial Results and Business Update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
earnings
-
Rhea-AI Summary
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) to Release Q2 Fiscal Year 2024 Financials on November 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Elite Pharmaceuticals files ANDA for generic drug product, FDA accepts for review
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
-
Rhea-AI Summary
Elite Pharmaceuticals appoints Carter Ward as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Elite Pharmaceuticals reports positive results from bioequivalence studies for undisclosed generic drug product in CNS stimulants class. IQVIA reports annual sales of $5.1B for this product. Generic product found to be bioequivalent to branded product. Elite plans to file Abbreviated New Drug Application with FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
Rhea-AI Summary
Elite Pharmaceuticals, Inc. announced its first quarter results for fiscal year 2024. Consolidated revenues for the period were $9.0 million, a 16.9% increase compared to the prior year. Operating profits increased by 60% to $1.6 million, and net income attributable to common shareholders increased by 267% to $1.1 million. The increase in operating profits was primarily due to increased manufacturing revenues from the launch of the Elite Laboratories label product line.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Elite Pharmaceuticals, Inc.

OTC:ELTP

ELTP Rankings

ELTP Stock Data

161.36M
845.24M
17.36%
0.01%
2.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Northvale

About ELTP

elite pharmaceuticals, inc. develops oral sustained and controlled release products. elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. elite has four anda products partnered with tagi pharma; one anda has launched, two andas are in the process of a manufacturing site transfer and an additional anda is currently under review by the fda. elite also manufactures lodrane d® and receives royalties for lodrane d®, an allergy product partnered with ecr pharmaceuticals (“ecr”), a wholly owned subsidiary of hi-tech pharmacal (“hi-tech”). elite’s lead pipeline products, eli-216, a once-daily abuse resistant oxycodone, and eli-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provisio